NCT03707353View on ClinicalTrials.gov

An Efficacy Study of IV Boosting With ChAd63/MVA ME-TRAP

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 30, 2018

Primary Completion Date

June 10, 2019

Study Completion Date

June 10, 2019

Conditions
Malaria
Interventions
BIOLOGICAL

ChAd63 ME-TRAP and MVA ME-TRAP vaccination

vaccination with ChAd63 ME-TRAP 5x10\^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10\^8 pfu (intramuscularly) and MVA METRAP 2x10\^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.

Trial Locations (4)

W12 0HS

NIHR Clinical Research Facility, Hammersmith Hospital, London

OX3 7LE

CCVTM, University of Oxford, Oxford

OX3 9DU

John Radcliffe Hospital, Oxford

SO16 6YD

Southampton National Institute for Health Research, Southampton

All Listed Sponsors
lead

University of Oxford

OTHER

NCT03707353 - An Efficacy Study of IV Boosting With ChAd63/MVA ME-TRAP | Biotech Hunter | Biotech Hunter